Judith Rosso, DO
Family Medicine · Gardnerville, NVNPI 1346246949
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 43 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $298, more than ten times the $21 reported in 2019.
Across 43 payments — averaging $19.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$144
- GSK$102
- Merck$95
- Otsuka America Pharmaceutical, Inc.$64
- Novartis$54
- Idorsia Pharmaceuticals US Inc$52
- plus $327 from 14 others
What the payments were for
- Food & beverage$81697%
- Education$213%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 6 | $144 |
| GSK | 7 | $102 |
| Merck | 4 | $95 |
| Otsuka America Pharmaceutical, Inc. | 3 | $64 |
| Novartis | 2 | $54 |
| Idorsia Pharmaceuticals US Inc | 3 | $52 |
| Pfizer | 2 | $40 |
| Tactile Systems Technology Inc | 2 | $34 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $34 |
| Tanabe Pharma America, Inc. | 1 | $30 |
| Amgen | 2 | $30 |
| Acadia Pharmaceuticals Inc | 1 | $24 |
| Boehringer Ingelheim | 1 | $21 |
| Eisai Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $19 |
| Abbott | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Lilly USA, LLC | 1 | $16 |
| Hologic Sales And Service, LLC | 1 | $15 |
| AstraZeneca | 1 | $11 |
How this compares
$837 in reported general payments places this provider in the 65th percentile of 902 family medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 65 | $75,938 |
| TrulicityDulaglutide | 46 | $63,857 |
| OzempicSemaglutide | 50 | $47,373 |
| JanuviaSitagliptin Phosphate | 29 | $36,045 |
| MounjaroTirzepatide | 30 | $31,938 |
| XareltoRivaroxaban | 20 | $28,327 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $27,675 |
| JardianceEmpagliflozin | 17 | $23,183 |
| TradjentaLinagliptin | 22 | $20,816 |
| Repatha SureclickEvolocumab | 23 | $15,519 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $8,992 |
| BelsomraSuvorexant | 16 | $7,713 |
| LinzessLinaclotide | 11 | $5,803 |
| Rosuvastatin Calcium | 342 | $5,645 |
| Levothyroxine Sodium | 572 | $5,449 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $16 | $95,79576 claims |
| PfizerEliquis | $40 | $75,93865 claims |
| Boehringer IngelheimJardiance, Tradjenta | $21 | $43,99939 claims |
| MerckJanuvia, Belsomra | $95 | $43,75845 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $102 | $41,10765 claims |
| AbbVieLinzess, Synthroid | $144 | $11,09090 claims |
| AstraZenecaSymbicort | $11 | $5,18816 claims |
| Eisai Inc.Dayvigo | $20 | $4,49914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 902 family medicine providers in Nevada.
Other family medicine in Gardnerville
- Naz WahabLas Vegas$563K
- Jerry CadeLas Vegas$180K
- Nilesh GokalLas Vegas$75K
- Bayo Curry-WinchellReno$74K
- Warren MagnusLas Vegas$70K
- Catherine McCarthyReno$68K
- Kimberly AdamsLas Vegas$51K
- Badi EghterafiHenderson$38K
- Francisco DofelizReno$30K
- Mandeep GillLas Vegas$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.